monoclonal antibody

Luzhu's major products are currently in the research and development stage and it does not have any approved products for sale, and has suffered a loss of over 1.5 billion yuan in the past three years.

FAST NEWS: Luzhu Biotech repurchases shares

The Latest: Beijing Luzhu Biotechnology Co. Ltd. (2480.HK) announced Monday that it repurchased a combined 1.43 million of the company’s shares on July 12 and 15, after its board authorized…
2480.HK

Recent Articles

RELATED ARTICLES

  1. Zhengye completes IPO, but more likely to come
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  2. Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  3. WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  6. Cancer drug maker Biostar shines on Hong Kong market debut
    2563.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva